Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation

International Journal of Hematology

Volumn 90, Issue 4, 2009, Pages 522-525

  Sever, Matjaz ^a   Kantarjian, Hagop ^a   Pierce, Sherry ^a   Jain, Nitin ^a   Estrov, Zeev ^a   Cortes, Jorge ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute myeloid leukemia; Cytogenetic abnormality; Essential thrombocythemia; Myelodysplastic syndrome; Myelofibrosis; Survival

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CHROMOSOME 13; CHROMOSOME 5; CHROMOSOME 9; CHROMOSOME ABERRATION; CHROMOSOME DELETION 5; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FOLLOW UP; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; SURVIVAL; THROMBOCYTHEMIA; THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD CELL COUNT; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL; YOUNG ADULT;

EID: 73449116359     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0411-5     Document Type: Article

References (28)

1. A Tefferi J Thiele A Orazi HM Kvasnicka T Barbui CA Hanson, et al. 2007 Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel Blood 110 4 1092 7 10.1182/blood-2007-04-083501 1:CAS:528:DC%2BD2sXptFKmurg%3D 17488875 (Pubitemid 47281402)
2. CS Chim YL Kwong AK Lie SK Ma CC Chan LG Wong, et al. 2005 Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia Arch Intern Med 165 22 2651 8 10.1001/archinte.165.22.2651 16344424 (Pubitemid 41785064)
3. N Gangat AP Wolanskyj RF McClure CY Li S Schwager W Wu, et al. 2007 Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients Leukemia 21 2 270 6 10.1038/sj.leu.2404500 1:STN:280:DC%2BD2s%2Fks1ejtA%3D%3D 17170720 (Pubitemid 46158119)
4. F Passamonti E Rumi L Arcaini E Boveri C Elena D Pietra, et al. 2008 Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients Haematologica 93 11 1645 51 10.3324/haematol.13346 18790799
5. A Tefferi N Gangat AP Wolanskyj S Schwager A Pardanani TL Lasho, et al. 2008 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis Eur J Haematol 80 5 386 90 10.1111/j.1600-0609.2008.01038.x 18221390
6. AP Wolanskyj SM Schwager RF McClure DR Larson A Tefferi 2006 Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors Mayo Clin Proc 81 2 159 66 10.4065/81.2.159 16471068
7. PG Heller PR Lev JP Salim LI Kornblihtt NP Goette CD Chazarreta, et al. 2006 JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status Eur J Haematol 77 3 210 6 10.1111/j.1600-0609.2006.00688.x 1:CAS:528: DC%2BD28XhtVSku7jK 16923108 (Pubitemid 44181383)
8. K Ohyashiki Y Aota D Akahane A Gotoh JH Ohyashiki 2007 JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders Leukemia 21 5 1097 9 1:CAS:528:DC%2BD2sXksFelt7s%3D 17315023
9. Z Rudzki T Sacha A Stoj S Czekalska M Wojcik AB Skotnicki, et al. 2007 The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study Int J Hematol 86 2 130 6 10.1532/IJH97.E0607 1:CAS:528:DC%2BD2sXhtFems7vK 17875526 (Pubitemid 47425190)
10. M Speletas E Katodritou C Daiou E Mandala E Papadakis A Kioumi, et al. 2007 Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders Leuk Res 31 8 1053 62 10.1016/j.leukres.2006.09.005 1:CAS:528:DC%2BD2sXmtlamsbs%3D 17045648
11. AM Vannucchi E Antonioli P Guglielmelli A Rambaldi G Barosi R Marchioli, et al. 2007 Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia Blood 110 3 840 6 10.1182/blood-2006-12-064287 1:CAS:528:DC%2BD2sXos1CqsL4%3D 17379742 (Pubitemid 47267419)
12. DP Steensma A Tefferi 2002 Cytogenetic and molecular genetic aspects of essential thrombocythemia Acta Haematol 108 2 55 65 10.1159/000064754 1:CAS:528:DC%2BD38Xmtleqsbg%3D 12187022 (Pubitemid 34983834)
13. U Bacher T Haferlach W Kern W Hiddemann S Schnittger C Schoch 2005 Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information Ann Hematol 84 4 250 7 10.1007/s00277-004-0977-1 15692838 (Pubitemid 40425072)
14. N Gangat A Tefferi G Thanarajasingam M Patnaik S Schwager R Ketterling, et al. 2009 Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance Eur J Haematol 83 1 17 21 10.1111/j.1600-0609.2009. 01246.x 1:CAS:528:DC%2BD1MXos1yiu7o%3D 19236446
15. HH Hsiao Y Ito G Sashida JH Ohyashiki K Ohyashiki 2005 De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia Leuk Res 29 11 1247 52 10.1016/j.leukres.2005.03.011 1:CAS:528:DC%2BD2MXhtVWgs7%2FI 16164981 (Pubitemid 41297635)
16. AD Panani 2006 Cytogenetic findings in untreated patients with essential thrombocythemia In Vivo 20 3 381 4 16724675
17. AD Panani 2007 Single chromosomal abnormalities in Philadelphia-negative chronic myeloproliferative disorders In Vivo 21 5 867 70 18019426
18. M Sessarego R Defferrari AM Dejana AM Rebuttato G Fugazza E Salvidio, et al. 1989 Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study Cancer Genet Cytogenet 43 1 57 65 10.1016/0165-4608(89)90127-1 1:STN:280:DyaK3c%2Fgt1yrtw%3D%3D 2790773 (Pubitemid 19281690)
19. JW Vardiman NL Harris RD Brunning 2002 The World Health Organization (WHO) classification of the myeloid neoplasms Blood 100 7 2292 302 10.1182/blood-2002-04-1199 1:CAS:528:DC%2BD38XnvVGisrY%3D 12239137
20. R McClure M Mai T Lasho 2006 Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders Leukemia 20 1 168 71 10.1038/sj.leu.2404007 1:CAS:528:DC%2BD28XjvFChtrc%3D 16270039
21. T Koike Y Uesugi K Toba M Narita I Fuse M Takahashi, et al. 1995 5q-syndrome presenting as essential thrombocythemia: myelodysplastic syndrome or chronic myeloproliferative disorders? Leukemia 9 3 517 8 1:STN:280: DyaK2M7ptFWqsQ%3D%3D 7885050
22. MD Reis GD Sher A Lakhani ID Dube JS Senn PH Pinkerton 1992 Deletion of the long arm of chromosome 5 in essential thrombocythemia Cancer Genet Cytogenet 61 1 93 5 10.1016/0165-4608(92)90376-J 1:STN:280:DyaK38zks1GgsA%3D%3D 1638486
23. H Takahashi T Furukawa S Hashimoto N Kanazawa N Satoh N Suzuki, et al. 2000 5q- syndrome presenting chronic myeloproliferative disorders-like manifestation: a case report Am J Hematol 64 2 120 3 10.1002/(SICI)1096- 8652(200006)64:2<120::AID-AJH9>3.0.CO;2-M 1:STN:280:DC%2BD3c3nsFCgtw%3D%3D 10814992 (Pubitemid 30324470)
24. J Welborn 1993 5q- in essential thrombocythemia Cancer Genet Cytogenet 67 2 150 10.1016/0165-4608(93)90172-I 1:STN:280:DyaK3szitFWrsQ%3D%3D 8330275 (Pubitemid 23198848)
25. M Sanada N Uike K Ohyashiki K Ozawa W Lili A Hangaishi, et al. 2007 Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms Leukemia 21 5 992 7 1:CAS:528:DC%2BD2sXksFeltLc%3D 17315020
26. JL Betz AS Behairy P Rabionet B Tirtorahardjo MW Moore PD Cotter 2005 Acquired inv(9): what is its significance? Cancer Genet Cytogenet 160 1 76 8 10.1016/j.cancergencyto.2004.12.002 1:CAS:528:DC%2BD2MXltFaqsL0%3D 15949575 (Pubitemid 40798141)
27. AM Udayakumar AV Pathare D Dennison JA Raeburn 2009 Acquired pericentric inversion of chromosome 9 in acute myeloid leukemia J Appl Genet 50 1 73 6 1:STN:280:DC%2BD1M7itVSmsw%3D%3D 19193987
28. TS Wan SK Ma LC Chan 2000 Acquired pericentric inversion of chromosome 9 in essential thrombocythemia Hum Genet 106 6 669 70 10.1007/s004390050041 1:CAS:528:DC%2BD3cXkt1erurY%3D 10942117 (Pubitemid 30427023)